Sigilon Therapeutics Announces Strategic Reprioritization
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living TherapeuticsTM platform, today announced a strategic reprioritization to enable the Company to focus on MPS-1 and diabetes.“There have been key learnings in our Phase 1/2 trial […]
English 
Español de Puerto Rico